Bristol Myers - Celgene CVRPreferred / convertible
13F holders, Q4 2024 (December 31)20holders −1
2new positions
4sold out
$6.87avg. 13F price*
At the end of Q4 2024, 20 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, down 1 from Q3 2024. 2 opened new positions and 4 sold out. The largest holders were FourWorld Capital Management LLC ($5.7M), Murchinson Ltd. ($700K) and Maven Securities LTD ($47K).
- Company
- Bristol Myers - Celgene CVR
- CUSIP
- 110122140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $747K |
| Exits | 4 | $8K |
All 13F filers, Q3 2024 → Q4 2024: 478,229 shares bought and 162,781 shares sold, net +315,448 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| FourWorld Capital Management LLC | — | No change | 100,000 | $5.7M |
| Murchinson Ltd. | — | New | 400,000 | $700K |
| Maven Securities LTD | — | New | 67,856 | $47K |
| Transcend Capital Advisors, LLC | — | No change | 117,775 | $6K |
| DAVENPORT & Co LLC | — | No change | 83,970 | $4K |
| Bank of America Corp. | — | No change | 51,638 | $3K |
| Purkiss Capital Advisors LLC | — | — | 26,450 | $1K |
| Two Sigma Securities, LLC | — | Add +65.8% | 26,144 | $1K |
| Fifth Third Bancorp | — | No change | 20,000 | $980 |
| Watts Gwilliam & Co., LLC | — | No change | 20,000 | $803 |
| Private Advisor Group, LLC | — | No change | 15,000 | $735 |
| UBS Group AG | — | Reduce -45.2% | 2,008 | $98 |
| Northwestern Mutual Wealth Management Co. | — | No change | 341 | $17 |
| Rothschild Investment LLC | — | No change | 166 | $8 |
| Morgan Stanley | — | No change | 119 | $6 |
| Oakworth Capital, Inc. | — | No change | 125 | $6 |
| JPMorgan Chase & Co. | — | No change | 23 | $1 |
| Wells Fargo & Company | — | No change | 28 | $1 |
| Atlantic Edge Private Wealth Management, LLC | — | No change | 16 | $1 |
| Royal Bank of Canada | — | No change | 2,475 | $0 |
"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.